Folic acid conjugated magnetic drug delivery system for controlled release of doxorubicin
Source abstract
Abstract
Targeting tumors by means of their vascular endothelium is a promising strategy, which utilizes targets that are easily accessible, stable, and do not develop resistance against therapeutic agents. Folate receptor is a highly specific tumor marker, frequently over expressed in cancer tumors. In the present study, an active drug delivery system, which can effectively target cancer cells by means of folate receptor-mediated endocytosis, have ability to escape from opsonization and capability of magnetic targeting to withstand the drag force of the body fluid have been designed and synthesized. The core of the drug delivery system is of mono-domain magnetic particles of magnetite. Magnetite nanoparticles are shielded with PEG, which prevents their phagocytosis by reticuloendothelial system. These PEG shielded magnetite nanoparticles are further decorated with an antitumor receptor—folic acid and loaded with an antineoplastic agent doxorubicin. An in vitro drug loading and release kinetics study reveals that the drug delivery system can take 52 % of drug load and can release doxorubicin over a sustained period of 7 days. The control and sustained release over a period of several days may find its practical utilities in chemotherapy where frequent dosing is not possible.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Barrera C, Herrera A, Zayas Y, Rinaldi C (2009) Surface modification of magnetite nanoparticles for biomedical applications. J Magn Magn Mater 321:1397–139910.1016/j.jmmm.2009.02.046 ↗
2. Brannon-Peppas L, Blanchette J (2004) Nanoparticles and targeted systems for cancer therapy. Adv Drug Del Rev 56:1649–165910.1016/j.addr.2004.02.014 ↗
3. Caliceti P, Salmaso S, Semenzato A, Carofiglio T, Fornasier R, Fermeqlia M, Ferrone M, Pricl S (2003) Synthesis and physicochemical characterization of folate: cyclodextrin bioconjugate for active drug delivery. Bioconjugate Chem 14:899–90810.1021/bc034080i ↗
4. Cascante M, Centelles J, Veech R, Lee W, Boros L (2000) Role of thiamin (Vitamin B1) and transketolase in tumor cell proliferation. Nutr Cancer 36:150–15410.1207/S15327914NC3602_2 ↗
5. Dreborg S, Akerblom E (1990) Immunotherapy with monomethoxypolyethelene glycol modified allergens. Crit Rev Ther Drug Carrier Sys 63:15–365
6. Fornari F, Randolph J, Yalowich J, Ritke M, Gewirtz D (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 45:649–65610.1016/S0026-895X(25)10149-1 ↗
7. Gupta A, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–402110.1016/j.biomaterials.2004.10.012 ↗
8. Harris J (1985) Laboratory synthesis of polyethelene glycol derivatives. J Macromol Sci, Rev Macromol Chem Phys C25:325–37310.1080/07366578508081960 ↗
9. Kaul G, Amiji M (2002) Long-circulating poly (ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res 19:1061–106710.1023/A:1016486910719 ↗
10. Kiessling L, Gestwicki J, Strong L (2000) Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol 4:696–70310.1016/S1367-5931(00)00153-8 ↗
11. Koda J, Venook A, Walser E, Goodwin S (2002) Phase I/II trial of hepatic intraarterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocarcinoma. Eur J Cancer 38:S18
12. Komaki R, Putnam J, Cox J (1997) Thymic neoplasms. Curr Opin Oncol 9:156–16010.1097/00001622-199703000-00009 ↗
13. Lee K (2005) Stability of Ionic complexes prepared from plasmid DNA and self-aggregated chitosan nanoparticles. Macromol Res 13:542–54410.1007/BF03218494 ↗
14. Li Y, Afzaal M, Brien P (2006) The synthesis of ammine-capped magnetic (Fe, Mn, Co., Ni) oxide nanocrystals and their surface modification for aquous dispersibility. J Mater Chem 16:2175–218010.1039/b517351e ↗
15. Lin C, Chiang RJ, Sung T (2006) Magnetic nanoproperties of monodispersed iron oxide nanoparticles. J App Phys 99: 08N710
16. Lopez-Quintela M, Rivas J (1993) Chemical reactions in microemulsions: a powerful method to obtain ultrafine particles. J Coll Interface Sci 158:446–45110.1006/jcis.1993.1277 ↗
17. Luangtana-anan M, Nunthanid J, Limmatvapirat S (2010) Effect of molecular weight and concentration of polyethylene glycol on physicochemical properties and stability of shellac film. J Agric Food Chem 58:12934–1294010.1021/jf1031026 ↗
18. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D (1996) Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56:4694–4701
19. Lübbe A, Alexiou C, Bergmann C (2001) Clinical applications of magnetic drug targeting. J Surg Res 95:200–20610.1006/jsre.2000.6030 ↗
20. Ma M, Zhang Y, Yu W, Shen H, Zhang H, Gu N (2003) Preparation and characterization of magnetite nanoparticles coated by amino silane. J Colloids surf A: 212–21910.1016/S0927-7757(02)00305-9 ↗
21. Maed H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–28410.1016/S0168-3659(99)00248-5 ↗
22. Mohapatra S, Mallick S, Maiti T, Ghosh S, Pramanik P (2007) Synthesis of highly stable folic acid conjugate magnetite nanoparticles for targeting cancer cells. Nanotechnology 18:38510210.1088/0957-4484/18/38/385102 ↗
23. Pankhurst Q, Connolly J, Jones S, Dobson J (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D 36:R167–R18110.1088/0022-3727/36/13/201 ↗
24. Park J, An K, Hwang Y, Park J, Noh H, Kim J, Park J, Hwang N, Hyeon T (2004) Ultra-large-scale syntheses of monodisperse nanocrystals. Nature Mater 3:891–89510.1038/nmat1251 ↗
25. Plank C (2009) Nanomedicine: silence the target. Nat Nanotechnol 4:544–54510.1038/nnano.2009.251 ↗
26. Prozorov T, Prozorov R, Koltypin Yu, Felner I, Gedanken A (1998) Sonochemistry under an applied magnertic field: determining the shape of a magnetic particle. J Phys Chem B 102:10165–1016810.1021/jp982453k ↗
27. Reddy J, Allagadda V, Leamon C (2005) Targeting therapeutics and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol 6:131–15010.2174/1389201053642376 ↗
28. Sahoo S, Labhasetwar V (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today 8:1112–112010.1016/S1359-6446(03)02903-9 ↗
29. Sugimoto T, Matijevic E (1980) Formation of uniform spherical magnetite particles by crystalization from ferrus hydroxyde gels. J Coll Interface Sci 74:227–24310.1016/0021-9797(80)90187-3 ↗
30. Sun S, Zeng H (2002) Size controlled synthesis of magnetite nanoparticles. J Am Chem Soc 124:8204–820510.1021/ja026501x ↗
31. Sun S, Zeng H, Robinson D, Raoux S, Rice P, Wang S, Li G (2004) Monodispersed MFe2O4 (M = Fe, Co., Mn)nanoparticles. J Am Chem Soc 126:273–27910.1021/ja0380852 ↗
32. Sun C, Sze R, Zhang M (2006) Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MIR. J Biomed Mater Res, Part A 78A:550–55710.1002/jbm.a.30781 ↗
33. Takakura Y, Maruyama K, Yokoyama M (1999) Passive targeting of drugs. Drug Deliv Syst 14:425–42610.2745/dds.14.425 ↗
34. Tang Z, Sorensen C, Klabunde K, Hadjipanayiss G (1991) Preparation of manganese ferrite fine particles from aqueous solution. J Coll Interface Sci 146:38–5210.1016/0021-9797(91)90004-R ↗
35. Wilson M, Kerlan R, Fidleman N (2004) Hepatocellular carncinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite- initial experience with 4 patients. Radiology 230:287–29310.1148/radiol.2301021493 ↗
36. Xie J, Peng S, Brower N, Pourmand N, Wang S, Sun S (2006) One-pot synthesis of monodisperse iron oxide nanoparticles for potential biomedical applications. Pure Appl Chem 78:1003–101410.1351/pac200678051003 ↗
37. Xu Q, Xubu JinC (2005) Self-aggregates of cholic acid hydrazide-dextran conjugates as drug carriers. J Appl Polymer Sci 95:487–49310.1002/app.21198 ↗
38. Ye X, Daraio C, Wang C, Talbot J, Jin S (2006) Room temperature solvent free synthesis of monodisperse magnetite nanocrystals. J Nanosci Nanotechnol 6:852–85610.1166/jnn.2006.135 ↗
39. Yokoyama M, Okano T (1996) Targetable drug carriers: present status and a future perspective. Adv Drug Deliv Rev 21:77–8010.1016/S0169-409X(96)00439-5 ↗
40. Zhang J, Misra R (2007) Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticles carriers and drug release response. Acta Biomater 3:838–85010.1016/j.actbio.2007.05.011 ↗
41. Zhang J, Srivastava R, Misra R (2007) Core-shell magnetite nanoparticles surface encapsulated with smart stimuli-responsive polymer: synthesis, characterization, and LCST of viable drug- targeting delivery systems. Langmuir 23:6342–635110.1021/la0636199 ↗
42. Zhang J, Rana S, Srivastava R, Misra R (2008) On the chemical synthesis and drug delivery response of folate receptor-activated, polyethylene glycol functionalized magnetic nanoparticles. Acta Biomater 4:40–4810.1016/j.actbio.2007.06.006 ↗